THE Therapeutic Goods Administration has approved MSD's anti-PD1 immunotherapy Keytruda (pembrolizumab) for the treatment of both metastatic first-line and advanced second-line non-small-cell lung cancer (NSCLC).
The approval means Australians with metastatic lung cancer can receive the drug without having first failed chemotherapy treatment.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Mar 17
